Vitasora Accelerates Patient Growth with vCare Platform Rollout and Cost Cuts

vCare Platform Drives Cost Savings and Efficiency

Vitasora Health Limited (ASX:VHL) has completed the rollout of its proprietary vCare Electronic Medical Record (EMR) platform, marking a pivotal step in its US remote patient monitoring (RPM) and chronic care management (CCM) operations. Operational since 1 April 2026, vCare replaces legacy systems with a unified platform designed to streamline enrolments, enhance workforce flexibility, and safeguard reimbursement integrity.

The upcoming launch of the RPM module, slated for 1 July 2026 pending final validation, will complete the transition from the Ceras platform. This shift is expected to slash software-as-a-service (SaaS) costs by more than 90%, reducing per-patient monthly fees from around US$7 to under US$1. Combined with workflow automation and reduced third-party dependencies, Vitasora anticipates total annualised operating savings of approximately US$1.7–1.8 million (AUD$2.4–2.6 million), substantially improving operating leverage.

Patient Enrolments Surge Amid Platform Transition

Patient enrolment activity has accelerated sharply following the platform implementation. April saw 469 new patients enrolled, nearly double the average monthly enrolments in February and March. Early May trends suggest a run-rate exceeding 550 patients per month, a growth of over 130% compared to the first quarter.

With an existing client patient base of around 40,000 entering an accelerated enrolment phase, Vitasora estimates that every additional 1,000 active patients could generate US$70,000 to US$120,000 in monthly revenue, depending on care mix and reimbursement pathways. At an average fee-for-service rate of US$85 per patient per month, reaching approximately 6,500 billed patients would support a monthly fee-for-service revenue of about US$550,000, aligning with the company’s forecast business-as-usual profitability threshold.

Improved Cash Collections and Path to Profitability

Vitasora has also made meaningful progress on cash flow, collecting approximately US$490,000 from the US$990,000 accounts receivable balance at 31 March. Notably, receivables aged over 60 days have decreased by around 30%, and those over 90 days by about 40%, reflecting enhanced collection efforts and operational discipline.

Management remains focused on reaching monthly business-as-usual cashflow breakeven in the second half of calendar 2026, supported by enrolment momentum and operational efficiencies. This target is consistent with the company’s previous guidance following its A$11 million capital raise earlier this year, which underpinned its US expansion strategy and growth ambitions A$11M to Accelerate US Connected Care Expansion.

Strategic Positioning in a Competitive Market

Vitasora’s proprietary vCare platform and FDA-approved wheezo® medical device differentiate it in the crowded digital health space, enabling comprehensive chronic disease management with remote wheeze detection. The company’s focus on integrating advanced technology with clinical expertise aims to improve patient outcomes while controlling costs, a critical factor as value-based care models gain traction in the US healthcare system.

Earlier in 2026, Vitasora reported a 22% increase in daily clinical billing productivity and anticipated a 10–20% revenue uplift from CMS reimbursement changes, indicating strong operational momentum that complements the current platform rollout Boosts Daily Billing 22 Percent.